Financial news reports that Shandong Xinde Technology Co., Ltd., known as Xinde Technology, has seen its Hong Kong IPO prospectus, submitted on February 16, 2026, lapse after a six-month period, becoming invalid as of August 16, 2026. At the time of filing, ICBC International and CITIC Securities International served as its joint sponsors.

According to the prospectus, Xinde Technology was founded in 1999 and is a leading animal health company in China. The firm focuses on the research, development, production, and sales of a full range of animal health and related products, including veterinary biologics (such as vaccines, antibodies, and transfer factors), traditional Chinese veterinary medicine, chemical pharmaceutical preparations, animal feed, and feed additives. These products aim to prevent, diagnose, treat, and control diseases in poultry, livestock, aquatic animals, and pets.

Based on data from Frost & Sullivan, by 2024 revenue, Xinde Technology ranked as the ninth-largest domestic manufacturer in China's animal health market and was among the top three players in the Chinese poultry veterinary biologics market.